News >

Cost of Biologics Therapy Soars Above Other Cancer Expenses

Tony Hagen @oncobiz
Published: Wednesday, Apr 06, 2016

Debra Patt, MD, MPH, MBA

Debra Patt, MD, MPH, MBA

Biologics therapy spending soared several hundred percent from 2004 to 2014; but despite rising treatment costs in general, oncology spending kept pace with spending for all categories of medical care, according to a report on Medicare and commercial data from the Community Oncology Alliance (COA).

“There has been a long-held belief in research and policy circles that cancer care costs in America have gone up disproportionately as compared to other health care costs,” said Debra Patt, MD, MPH, MBA, a practicing oncologist at Texas Oncology and a COA board and study team member. “This study shows that this commonly held belief is not supported by the evidence.”

The study by Milliman, a global actuarial and consulting firm, also noted a dramatic shift in site-of-service for chemotherapy infusion from community oncology centers to more expensive hospital outpatient departments, which has added to the rise in the cost of cancer care overall.

For example, whereas roughly 90% of commercially insured chemotherapy infusion was done in physician offices in 2004, by 2014 nearly 60% of commercial infusion was being done in hospital outpatient centers, according to the report (Table 1). The report estimated that Medicare would have saved $2 billion had there been no change in site-of-service for chemotherapy infusion from 2004 to 2014.

Table 1: Infused chemotherapy drug spending by site of service

Table 1: Infused chemotherapy drug spending by site of service

Source: Based on Milliman analysis of the 2004-2014 Truven MarketScan data and Medicare 5% sample data

Various categories of oncology care spending went up dramatically, according to the report, which distinguished between Medicare and commercial payer spending on these items. From 2004 to 2014, Medicare spending on emergency department care rose 132%, whereas related commercial spending was up 147%. For radiation oncology the respective numbers were 204% and 66%; and for biologic chemotherapy, 335% and 485% (Table 2).

Among the less dramatic increases were hospital inpatient admissions, which saw a 22% increase in Medicare spending versus 44% commercial; and cytotoxic therapy up 14% and 101%, respectively.

While drug spending was up sharply, it amounted to just one-fifth of total costs among actively treated cancer patients in 2014, the report said. Therefore, overly focusing on drug costs in the effort to reduce overall oncology spending would be a misguided strategy, said Ted Okon, executive director of COA. The report comes out just shortly after The Centers for Medicare & Medicaid Services announced a plan to modify physician reimbursement for Medicare Part B drug expenses. Okon said the findings are evidence that the proposed adjustment to payment rates would add to the difficulties of running an independent oncology practice and accelerate the trend of consolidation among cancer treatment centers that is contributing to higher costs of care.

Table 2: 2004 to 2014 allowed cost trend by major service category for actively treated patients — Medicare and commercial

Table 2: 2004 to 2014 allowed cost trend by major service category for actively treated patients — Medicare and commercial

Source: Based on Milliman analysis of the 2004-2014 Truven MarketScan data and Medicare 5% sample data

Okon said the report shows that more attention needs to be paid to the use of radiation therapy, given that the increase in spending in this category was among the highest of those looked at. “I think we have to do a better job in general of making sure all of that is appropriate use.” An evaluation also needs to be made of emergency department use, given the findings, Okon said.

The report included an analysis of site-of-care payment differences between outpatient centers and independent oncology clinics offering chemotherapy infusion. The report cited a $6,500 lower cost on average for Medicare beneficiaries receiving chemotherapy infusion at a physician’s office versus a hospital outpatient setting.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x